Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6005 Target Snapshot

Serine/threonine-protein kinase 33 · SINGLE PROTEIN · Homo sapiens

596Compounds
211Assays
8Approved Drugs
183.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9BYT3. Use UniProt Q9BYT3 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9BYT3 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase 33 as ChEMBL target CHEMBL6005, mapped to UniProt Q9BYT3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase 33
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL6005
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9BYT3
Serine/threonine-protein kinase 33
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase 33 is the right protein anchor across sources, using UniProt Q9BYT3 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase 33
UniProt AccessionQ9BYT3
Component TypeProtein
Sequence Length514 aa

Serine/threonine-protein kinase 33

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase 33, mapped to UniProt Q9BYT3. Sequence length is 514 aa.

Mapped IDQ9BYT3
Review nameSerine/threonine-protein kinase 33
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

8
Approved
7
Phase III
5
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5052.0
KI8.0
KD123.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 8.74 Kd 1.8 Preclinical
CHEMBL509032 8.49 Kd 3.2 Preclinical
CHEMBL4576489 8.22 Kd 6.0 Preclinical
CHEMBL2203524 8.15 IC50 7.0 Preclinical
CHEMBL4465866 8.1 Kd 8.0 Preclinical
CHEMBL2203525 7.96 IC50 11.0 Preclinical
CHEMBL2204239 7.85 IC50 14.0 Preclinical
CHEMBL535 7.77 Kd 17.0 Approved
CHEMBL603469 7.58 Kd 26.0 Clinical
CHEMBL388978 7.44 IC50 36.3 Preclinical
Distribution

pChEMBL Value Distribution

13
5.0
18
5.5
14
6.0
15
6.5
8
7.0
8
7.5
4
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
MIDOSTAURIN
CHEMBL608533
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
BOSUTINIB
CHEMBL288441
Approved 2012
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

211
Total Assays
61
Tested Compounds
2
Assay Types
Binding — 210 assays, 61 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 173 58 6.5
assay format 23 0
cell-based format 10 3 7.0
subcellular format 4 0
Functional — 1 assays, 5 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 5 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine